# Seventh Annual Report on Schizophrenia Pharmacotherapy in VA

FY 2005

Douglas L. Leslie, Ph.D. and Robert Rosenheck, M.D.

Northeast Program Evaluation Center, West Haven VAMC; VA Connecticut Mental Illness Research, Education and Clinical Center; VA Connecticut Clinical Epidemiology Research Center; and the Departments of Psychiatry and Epidemiology/Public Health, Yale School of Medicine, New Haven, CT

Address correspondence to:

Douglas L. Leslie, Ph.D. NEPEC/182 950 Campbell Ave. West Haven, CT 06516

## **Abstract**

Background: Pharmacotherapy is the cornerstone of effective treatment for schizophrenia. This report presents a profile of the use of antipsychotic medications in the treatment of schizophrenia in the Department of Veterans Affairs nationwide.

Methods: Patients were identified as being diagnosed with schizophrenia if they had at least two outpatient encounters with a diagnosis of schizophrenia during fiscal year (FY) 2005. All VA prescription drug records for antipsychotic medications written during FY 2005 were then collected for these patients. Patients who received a prescription for an antipsychotic medication were identified. Taking the last antipsychotic prescription during this period and going back seven days, all antipsychotic medications that were prescribed and the amount prescribed for each patient receiving an antipsychotic were identified. Measures of polypharmacy and compliance with PORT recommendations were constructed from these data, as well as indicators reflecting the use of atypical antipsychotics, and compared with the values from FY 2004.

Results: Of the 90,678 patients in the final sample with schizophrenia, 76,787 received at least one prescription for an antipsychotic medication (84.7%), which represented an increase of 0.5% from the FY 2004 level. Of these patients, 7,118 (9.3%) met criteria for polypharmacy, which is an increase of 0.3% from FY 2004. The majority of patients (47,562 or 61.9%) were dosed within the PORT recommended range, while 10,867 (14.2%) were dosed above the PORT recommendations, an increase of 1.6% from the FY 2004 level. Of the patients who received atypical antipsychotics (63,883 or 83.2%), most received either risperidone (23,275 or 36.4%) or olanzapine (16,674 or 26.1%). Slightly

fewer patients received quetiapine (15,326 or 24.0%), and far fewer received aripiprazole (5,364 or 8.4%), ziprasidone (3,819 or 6.0%) or clozapine (2,026 or 3.2%). Compared to FY 1999 levels, the first year for which these data are available, there has been a dramatic shift from conventional to atypical antipsychotic medications.

Conclusions: The proportion of patients with schizophrenia who received an antipsychotic medication in FY 2005 remained fairly constant compared to the FY 2004 level. However, the percentage of patients dosed within the PORT recommended range fell by 2.1%, driven primarily by an increase of 1.6% in the proportion of patients dosed above the recommendations. The proportion of patients receiving more than one antipsychotic medication increased slightly (0.3%) to 9.3%. The number of outpatients diagnosed with schizophrenia who received an atypical antipsychotic is leveling off over time, although the use of quetiapine and aripiprazole has grown while fewer patients were prescribed olanzapine.

# I. Introduction

Pharmacotherapy has long been the cornerstone of treatment for schizophrenia. As health care systems respond to pressures to reduce the costs of care, there is a growing concern that quality be systematically monitored and preserved. Performance assessment based on clinically derived practice guidelines provides one mechanism for evaluating the quality of care in a clinical practice or organization. The Schizophrenia Patient Outcomes Research Team (PORT) has developed one widely respected set of guidelines for the treatment of schizophrenia (1).

The Veterans Health Administration of the Department of Veteran Affairs (VA) has not been immune to pressures to reduce health care costs. In 1995, VA experienced a major reorganization in which 22 distinct geographically based Veterans Integrated Service Networks (VISNs) were created, each responsible for the veteran population within its boundaries. An associated goal of the reorganization was to shift the focus of care away from acute inpatient care and towards more ambulatory and primary care in order to improve the accessibility of services and to address anticipated budget reductions (2). Between 1995 and 1999, total mental health expenditures declined by 13%, even without adjustment for inflation (3).

Pharmacologic treatment of schizophrenia has changed in recent years with the introduction of newer atypical antipsychotic medications. These medications (i.e. clozapine, olanzapine, risperidone, quetiapine, and, most recently, ziprasidone and aripiprazole) are considered to be equally or more effective than conventional antipsychotic medications and to have substantially superior side effect profiles.

However, these medications are considerably more expensive than conventionals, with annual costs averaging \$3,000 - \$5,000, 10 times the \$300 average annual cost of treatment with haloperidol.

As part of an ongoing effort to monitor quality of mental health care in VA (4-7), this report serves three functions: 1) it examines the extent to which pharmacotherapeutic care for patients diagnosed with schizophrenia conforms to the schizophrenia PORT treatment guidelines, 2) it investigates the availability of atypical antipsychotics to patients in VA, and 3) it tracks changes over time in these aspects of pharmacotherapeutic care for schizophrenia.

## II. Methods

# Sources of data

Data for the study come from national VA administrative databases. First, all VA outpatients diagnosed with schizophrenia during fiscal year (FY) 2005 (October 1, 2004 to September 30, 2005) were identified. Patients were identified as being diagnosed with schizophrenia if they had at least two outpatient encounters in a specialty mental health outpatient clinic with a primary or secondary diagnosis of schizophrenia (ICD-9 codes 295.00 – 295.99). The outpatient encounter file, a national database of information concerning all outpatient clinic stops in VA, was used to identify these patients. Next, all outpatient prescription drug records for these patients during FY 2005 were collected from the Decision Support System (DSS) Pharmacy file for FY 2005.

#### Measures

First, for each patient who received a prescription for an antipsychotic medication, the last prescription for an antipsychotic medication filled in FY 2005 was identified as the index prescription. All prescriptions for antipsychotic medications written during the 7 days prior to the index prescription were then identified. Next, chlorpromazine (CPZ) equivalents were calculated for each prescription for a conventional antipsychotic medication based on the updated PORT dosing algorithms (A. Lehmann, personal communication). CPZ equivalents were summed over all conventional antipsychotic prescriptions during the week to assess guideline adherence. If the total daily CPZ equivalent for all conventional antipsychotics prescribed during the week was greater than the PORT recommendation (1000 mg), the patient was identified as being dosed too high. For the atypical antipsychotics, the total daily dosage for each medication prescribed during the week was calculated. If the total dosage of any atypical was greater than the recommended range, the patient was identified as being dosed too high. In addition, a patient was also identified as being dosed too high if they were prescribed the maximum recommended dose of one atypical and were also prescribed any amount of a second atypical.

-

<sup>&</sup>lt;sup>1</sup> The maximum PORT recommended dose for atypical antipsychotic medications are as follows: clozapine 600 mg/day, olanzapine 20 mg/day, quetiapine 450 mg/day and risperidone 6 mg/day. For ziprasidone and aripiprazole, the maximum recommended dose was obtained from the product labels for these drugs (160 mg/day and 30 mg/day, respectively).

Although prescribing multiple antipsychotic medications is not addressed in the PORT guidelines, polypharmacy generally is not recommended for schizophrenia patients because additional medications may exacerbate side effects while doing little to alleviate symptoms (8, 9). Patients who were prescribed more than one antipsychotic medication during the week were identified as receiving polypharmacy. In addition, the subgroup of patients whose polypharmacy consisted of receiving both an atypical and a conventional antipsychotic medication was examined.

# Analysis

Data analysis proceeded in several steps. First, the proportion of patients with the following characteristics were determined: 1) those who received multiple antipsychotic medications, 2) those who dose was within the PORT recommended range, 3) those who were dosed above the PORT recommendation with any medication, 4) those who were dosed above the PORT recommendation with a conventional antipsychotic, 5) those who were dosed above the PORT recommendation with an atypical antipsychotic, 6) those who received any atypical antipsychotic, and 7) through 12) those who received the specific atypical antipsychotic medications clozapine, olanzapine, quetiapine, risperidone, ziprasidone or aripiprazole among patients receiving any atypical. Means of these measures were calculated by station and by VISN, as well as the percent change from their FY 2004 levels.

# III. Results

Table 1 shows characteristics of the sample. Of the 90,678 patients diagnosed with schizophrenia during FY 2005 who received their medications from VA pharmacies,

76,787 (84.7%) received an antipsychotic medication. Few patients were treated with multiple antipsychotic medications (9.3%). A higher proportion (14.2%) was prescribed a dose that was higher than the recommended range, with most of these patients being dosed too high on an atypical antipsychotic medication. The majority (83.2%) of patients received an atypical antipsychotic. This represents an increase of 1.4% from the FY 2004 level and an increase of 24.4% from the FY 1999 figure, the first year that these data were available (Figure 1). Among patients prescribed an atypical, most received either risperidone (36.4%) or olanzapine (26.1%), with a smaller proportion receiving quetiapine (24.0%), and much smaller proportions receiving aripiprazole (8.4%), ziprasidone (6.0%), or clozapine (3.2%).

Tables 2 and 3 report pharmacy measures at the level of the VISN and the facility, respectively. The coefficient of variation at the bottom of each table indicates the amount of variation among VISNs and facilities. At both the VISN level and the facility level, variation was relatively high for the percentage of patients prescribed clozapine and the percentage of patients dosed high on conventionals. Variation was small for the percentage of patients prescribed any antipsychotic medication, the percentage of patients prescribed an atypical, and the percentage of patients dosed within the PORT recommended range.

# IV. Discussion

This study profiled pharmacologic treatment of patients with schizophrenia in VA. The proportion of patients who were treated with more than one antipsychotic medication, who were dosed above the schizophrenia PORT recommended dosage, and

who were prescribed an atypical antipsychotic medication were determined. Only a small proportion (9.3%) of patients were prescribed multiple antipsychotic treatment regimens, while a higher percentage (14.2%) were dosed above PORT guidelines. A majority of patients (83.2%) were prescribed an atypical antipsychotic, most often olanzapine or risperidone.

In previous work, we performed logistic regressions to explore the effects of patient and facility characteristics on the likelihood that patients with a diagnosis of schizophrenia who are prescribed an antipsychotic received an atypical medication, were dosed outside of the PORT recommended range or were prescribed polypharmacy (10-12). We found that older patients, Blacks and patients with a service connected disability were generally less likely to be prescribed an atypical, while patients with a comorbid mental health diagnosis were more likely to receive these medications. Older patients and those with a comorbid mental health diagnosis were less likely to be dosed above PORT guidelines, and older patients and Blacks were less likely to be prescribed multiple antipsychotic medications. The facility characteristics that we included in our models, which included measures of academic emphasis, reliance on inpatient care and fiscal stress, were generally not significant predictors of our quality measures.

A limitation of the analyses presented in this report relates to the difficulty in measuring prescribing patterns using administrative prescription data. Prescriptions may last for varying lengths of time. Patients with multiple prescriptions may run out of their medications and need to see their doctor to refill their prescriptions at different times.

We collect all prescription drug records during a one-week period, but a longer time

frame may be necessary to identify all of the drugs a particular patient is taking. Hence, our measures of polypharmacy or whether a patient is dosed above PORT guidelines may be underestimated.

While the proportions of patients diagnosed with schizophrenia who are prescribed multiple antipsychotic medications or who are prescribed a dose that exceeds PORT recommended range are fairly small, these phenomena are still a concern. These medications are studied extensively before they are approved for use, but trials typically do not include combinations with other antipsychotics or abnormally high doses. Hence, the effects of these treatment regimens are unknown. More research is needed to investigate why physicians are prescribing in this manner.

# References

- Lehman AF, Steinwachs DM, the Co-Investigators of the PORT Project:
   Translating Research into Practice: The Schizophrenia Patient Outcomes
   Research Team (PORT) Treatment Recommendations. Schizophrenia Bulletin
   1998; 24(1):1-10
- Rosenheck R, Horvath T: The Impact of VA Reorganization on Patterns of Mental Health Care. Psychiatric Services 1998; 49:53
- Rosenheck RA, DiLella D: Department of Veterans Affairs National Mental
   Health Program Performance Monitoring System: Fiscal Year 1999 Report. West
   Haven, CT, Northeast Program Evaluation Center, 2000
- Chen RS, Nadkarni PM, Levin FL, Miller PL, Erdos J, Rosenheck RA: Using a
  Computerized Hospital Database to Monitor Compliance of Pharmacotherapeutic
  Guidelines in the Treatment of Schizophrenia. Psychiatric Services 2000;
  51(6):791-4
- Leslie DL, Rosenheck RA: Comparing Quality of Mental Health Care in Public Sector and Privately Insured Populations: First Efforts and Methodological Challenges. Psychiatric Services 2000; 51(5):650-5
- 6. Rosenheck RA, Cicchetti D: A Mental Health Program Report Card: A

  Multidimensional Approach to Performance Monitoring in Public Sector

  Programs. Community Mental Health Journal 1998; 34(1):85-106

- 7. Rosenheck RA, Fontana A, Stolar M: Assessing Quality of Care: Administrative Indicators and Clinical Outcome Measures. Medical Care 1999; 37(2):180-188
- 8. Stahl SM: Antipsychotic Polypharmacy, Part 1: Therapeutic Option or Dirty Little Secret? Journal of Clinical Psychiatry 1999; 60(7):425-6
- 9. Stahl SM: Antipsychotic Polypharmacy, Part 2: Tips on Use and Misuse. Journal of Clinical Psychiatry 1999; 60(8):506-7
- Leslie DL, Rosenheck RA: Pharmacotherapeutic Treatment of Schizophrenia in the Department of Veterans Affairs: Prescribing Patterns and Guideline Adherence. West Haven, CT, Northeast Program Evaluation Center, 2000, pp 1-
- 11. Leslie D, Rosenheck R: The Effects of Institutional Fiscal Stress on the Use of Atypical Antipsychotic Medications in the Treatment of Schizophrenia. The Journal of Nervous and Mental Disease 2001; 189(6): 377-383
- 12. Leslie D, Rosenheck R: Use of Pharmacy Data to Assess Quality of Pharmacotherapy for Schizophrenia in a National Health Care System: Individual and Facility Predictors. Medical Care 2001; 39(9): 923-933

Table 1. Sample characteristics

	FY 2	2005	Change from	Change from
Variable	N	%	FY 2004	FY 1999
All patients	90,678	100.0%	-1.5%	-12.0% **
Prescribed any antipsychotic	76,787	84.7%	0.5%	3.8% **
Polypharmacy Receiving both atypical and conventional	7,118 3,459	9.3% 4.5%	0.3% -0.3%	2.5% -0.7%
Dose within PORT guidelines	47,562	61.9%	-2.1%	N/A
Dose higher than PORT guidelines Conventional antipsychotics Atypical antipsychotics	10,867 1,418 9,559	14.2% 1.8% 12.4%	1.6% -0.3% 1.9%	-0.5% -9.3% 3.7%
Dose lower than PORT guidelines Conventional antipsychotics Atypical antipsychotics	18,698 8,493 10,473	24.4% 11.1% 13.6%	0.6% -0.7% 3.1%	-4.5% ** -10.8% ** 6.4% **
Received any conventional antipsychotic	16,363	21.3%	-1.7%	-25.1%
Received any atypical antipsychotic Clozapine Olanzapine Quetiapine Risperidone Ziprasidone Aripiprazole	63,883 2,026 16,674 15,326 23,275 3,819 5,364	83.2% 3.2% 26.1% 24.0% 36.4% 6.0% 8.4%	1.4% 0.2% -5.6% 0.7% -0.5% 0.3% 4.9%	24.4% -2.0% -22.3% 19.7% -7.4% N/A ***

 $<sup>^{\</sup>star\star}$  Figures from FY 1999 not available. Figures from FY 2000 used instead.

<sup>\*\*\*</sup> Aripiprazole was new to the market in FY 2003; no patients received this drug before FY 2003. Ziprasidone was approved for use in 2001; no patients received this drug in FY 1999.

Figure 1. The Percentage of Patients Prescribed Atypical Antipsychotic Medications




Table 2a. VISN-level pharmacy measures -- Fiscal Year 2005

		prescr	ercent ribed any sychotic	polyp	cent with charmacy ast week	withir	nt dosed n PORT ended range	higher	ent dosed than PORT ended range	hi	ent dosed igh on entionals	h	ent dosed igh on ypicals	lower	ent dosed than PORT ended range	lo	ent dosed w on entionals	lo	nt dosed w on picals
			Change from		Change from		Change from		Change from		Change from		Change from		Change from		Change from		Change from
VISN	N	FY 2005	FY 2004	FY 2005	FY 2004	FY 2005	FY 2004	FY 2005	FY 2004	FY 2005	FY 2004	FY 2005	FY 2004	FY 2005	FY 2004	FY 2005	FY 2004	FY 2005	FY 2004
1	4,342	84.6%	2.9%	12.6%	0.8%	60.5%	-0.1%	15.6%	2.5%	7.2%	-0.4%	16.9%	2.8%	24.5%	-2.2%	55.2%	-2.2%	16.1%	-0.6%
2	2,477	84.1%	0.4%	11.8%	1.6%	56.0%	-3.6%	16.0%	0.8%	7.6%	1.5%	17.7%	0.1%	28.9%	3.2%	56.0%	-1.4%	18.6%	4.9%
3	4,799	83.6%	0.9%	10.7%	-0.2%	61.1%	-2.1%	14.7%	2.0%	9.9%	0.8%	15.4%	2.2%	24.7%	0.4%	48.4%	-0.9%	15.4%	1.6%
4	5,581	85.2%	0.4%	9.1%	-0.4%	59.4%	-2.0%	12.4%	1.8%	7.0%	-1.5%	13.5%	2.8%	28.9%	0.5%	52.9%	-0.5%	18.8%	1.8%
5	2,469	82.3%	-1.1%	11.6%	0.5%	63.1%	-3.4%	15.7%	3.7%	11.9%	1.3%	15.6%	4.0%	21.7%	0.0%	47.3%	0.2%	15.2%	0.1%
6	4,042	87.9%	2.3%	9.3%	1.3%	61.8%	-1.6%	12.8%	0.4%	10.4%	-0.4%	12.9%	0.6%	26.0%	1.5%	49.2%	0.0%	17.1%	2.3%
7	6,002	85.0%	-0.6%	8.3%	1.1%	64.3%	-1.5%	13.0%	1.8%	8.0%	-0.2%	13.5%	2.1%	23.1%	-0.2%	51.0%	0.5%	16.3%	-0.1%
8	9,115	83.1%	0.0%	6.3%	-0.2%	60.1%	-1.5%	12.3%	0.2%	10.2%	-4.0%	12.5%	1.3%	27.8%	1.3%	54.6%	2.3%	21.0%	2.5%
9	3,360	84.8%	1.1%	8.0%	1.2%	61.7%	-2.2%	12.8%	2.9%	7.0%	0.9%	14.0%	3.2%	25.8%	-0.6%	51.4%	-0.1%	17.3%	0.0%
10	4,355	86.0%	4.0%	9.6%	1.8%	61.9%	-1.5%	14.5%	2.6%	8.2%	-3.2%	15.6%	4.1%	24.2%	-1.0%	53.0%	2.2%	15.1%	-0.4%
11	4,580	87.8%	0.6%	8.8%	-0.4%	62.5%	-1.7%	16.6%	0.6%	13.5%	-0.9%	16.9%	1.3%	21.3%	1.0%	45.9%	2.2%	13.4%	1.6%
12	3,604	84.1%	0.9%	10.3%	1.2%	63.5%	-3.8%	12.5%	1.9%	6.5%	-1.3%	13.4%	2.5%	24.4%	1.8%	54.9%	2.3%	16.3%	1.9%
15	3,845	86.9%	0.0%	12.8%	0.1%	61.0%	-3.0%	14.8%	1.3%	9.5%	-0.4%	15.6%	1.9%	24.7%	1.7%	50.7%	2.0%	15.7%	2.1%
16	7,710	85.9%	0.0%	9.1%	0.2%	62.8%	-3.1%	15.0%	2.4%	8.6%	0.4%	16.0%	2.7%	22.6%	0.8%	51.4%	2.7%	15.2%	1.1%
17	3,773	83.5%	0.3%	8.3%	0.5%	65.0%	-2.5%	15.0%	1.2%	9.0%	0.3%	15.7%	1.4%	20.2%	1.2%	49.9%	0.8%	14.7%	1.7%
18	2,821	77.8%	-1.2%	6.1%	-0.3%	64.4%	-2.3%	8.9%	1.1%	3.9%	-1.1%	9.8%	1.6%	26.9%	1.1%	63.2%	0.8%	17.6%	1.7%
19	2,044	86.2%	-0.8%	11.1%	-0.3%	59.8%	-3.2%	16.4%	3.7%	6.3%	0.8%	17.9%	4.0%	24.6%	-0.4%	53.0%	1.4%	15.8%	-0.9%
20	3,514	85.7%	0.1%	7.5%	0.0%	64.4%	-0.2%	13.3%	-0.9%	8.9%	-1.4%	13.9%	-0.7%	22.6%	0.9%	51.2%	-1.4%	15.6%	2.1%
21	3,713	83.2%	-0.8%	10.1%	-0.5%	61.1%	-4.7%	18.1%	3.5%	8.2%	0.4%	19.2%	3.8%	21.3%	1.2%	50.1%	-0.6%	14.8%	2.0%
22	5,342	82.7%	0.9%	9.3%	0.8%	63.0%	-2.2%	14.1%	1.1%	7.2%	-0.7%	15.1%	1.2%	23.1%	1.1%	51.6%	1.5%	16.2%	1.7%
23	3,190	86.7%	-0.7%	9.4%	-0.4%	63.3%	-0.6%	15.5%	1.6%	8.7%	-0.7%	16.5%	1.9%	21.7%	-0.9%	53.5%	0.2%	14.1%	0.3%
Min		77.8%	-1.2%	6.1%	-0.5%	56.0%	-4.7%	8.9%	-0.9%	3.9%	-4.0%	9.8%	-0.7%	20.2%	-2.2%	45.9%	-2.2%	13.4%	-0.9%
Max		87.9%	4.0%	12.8%	1.8%	65.0%	-0.1%	18.1%	3.7%	13.5%	1.5%	19.2%	4.1%	28.9%	3.2%	63.2%	2.7%	21.0%	4.9%
Mean	4,318	84.6%	0.4%	9.5%	0.4%	61.9%	-2.2%	14.3%	1.7%	8.5%	-0.5%	15.1%	2.1%	24.2%	0.6%	52.1%	0.6%	16.2%	1.3%
Std. Dev.	1,715	2.2%	1.3%	1.8%	0.7%	2.1%	1.2%	2.0%	1.2%	2.1%	1.4%	2.1%	1.3%	2.5%	1.2%	3.6%	1.4%	1.7%	1.3%
Coeff. of Var.	0.40	0.03	2.8%	0.19	-4.5%	0.03	1.0%	0.14	-5.9%	0.24	-11.8%	0.14	-14.4%	0.10	-1.6%	0.07	-9.4%	0.11	-7.5%
					-														

Table 2b. VISN-level pharmacy measures -- Fiscal Year 2005 (continued)

		presc	ercent ribed any ventional	presc	ercent ribed any sypical	pre	ercent scribed zapine	pre	ercent escribed nzapine	pre	ercent scribed etiapine	pre	ercent scribed eridone	pre	ercent scribed asidone	pre	ercent scribed prazole
			Change from		Change from		Change from		Change from		Change from		Change from		Change from		Change from
VISN	N	FY 2005	FY 2004	FY 2005	FY 2004	FY 2005	FY 2004	FY 2005	FY 2004	FY 2005	FY 2004	FY 2005	FY 2004	FY 2005	FY 2004	FY 2005	FY 2004
1	4,342	20.8%	-2.7%	84.3%	2.8%	5.4%	1.2%	25.4%	-1.5%	19.8%	0.3%	29.4%	-0.5%	5.1%	0.9%	6.1%	2.9%
2	2,477	25.7%	-1.2%	79.6%	1.7%	3.2%	0.2%	20.1%	-4.9%	19.0%	1.0%	30.6%	2.2%	4.8%	0.7%	7.0%	2.6%
3	4,799	26.5%	-1.3%	79.4%	0.6%	1.8%	0.1%	21.8%	-3.7%	16.0%	0.6%	33.5%	-0.2%	3.0%	-0.1%	6.3%	3.5%
4	5,581	28.2%	-1.6%	77.3%	1.0%	2.0%	0.2%	21.1%	-2.5%	19.2%	0.3%	27.5%	0.3%	3.9%	-0.2%	3.9%	2.5%
5	2,469	19.8%	-0.8%	85.7%	0.3%	1.4%	0.0%	24.2%	-3.9%	17.6%	0.5%	28.9%	-2.1%	6.5%	0.9%	10.3%	4.4%
6	4,042	25.7%	-1.1%	79.7%	1.9%	1.5%	-0.2%	16.7%	-3.9%	19.5%	2.2%	31.7%	-0.6%	5.4%	0.0%	7.3%	3.9%
7	6,002	18.4%	-0.6%	85.7%	0.7%	2.3%	0.1%	19.8%	-3.9%	22.5%	-0.3%	31.2%	1.1%	6.4%	0.1%	6.9%	4.4%
8	9,115	19.5%	-3.4%	83.1%	2.4%	1.3%	0.2%	26.1%	-6.3%	20.1%	2.2%	27.7%	1.5%	3.7%	0.4%	7.2%	4.7%
9	3,360	24.6%	-1.6%	79.7%	1.9%	1.8%	-0.1%	15.9%	-5.3%	19.0%	0.7%	32.1%	1.6%	5.8%	-0.3%	6.9%	5.4%
10	4,355	23.4%	-2.7%	81.5%	2.7%	5.3%	2.6%	21.9%	-4.0%	20.5%	-0.2%	24.8%	-0.3%	5.2%	0.2%	7.3%	5.5%
11	4,580	23.3%	-2.4%	81.9%	1.6%	3.5%	0.1%	21.8%	-4.0%	16.6%	1.6%	35.6%	0.9%	3.1%	0.0%	3.7%	2.4%
12	3,604	20.2%	-0.7%	84.4%	0.8%	3.7%	0.3%	20.8%	-3.3%	18.1%	1.0%	34.5%	-1.0%	4.3%	0.0%	7.2%	4.2%
15	3,845	24.2%	-1.5%	82.9%	0.9%	1.4%	-0.6%	20.9%	-5.2%	20.7%	0.4%	30.8%	-0.6%	6.1%	0.6%	7.9%	6.1%
16	7,710	19.3%	-1.7%	84.8%	1.4%	1.7%	0.1%	17.3%	-4.3%	21.4%	0.3%	33.9%	-0.5%	5.8%	0.6%	8.2%	5.1%
17	3,773	14.5%	-1.6%	88.9%	1.2%	3.1%	-0.2%	22.5%	-5.8%	22.7%	1.8%	31.2%	0.4%	5.0%	0.2%	8.5%	5.3%
18	2,821	20.0%	-0.3%	83.2%	0.0%	1.5%	-0.2%	22.1%	-3.7%	19.2%	2.2%	29.8%	-1.1%	6.5%	0.6%	5.7%	1.8%
19	2,044	21.7%	0.2%	84.3%	0.0%	5.1%	0.3%	24.5%	-5.4%	19.1%	-0.8%	29.9%	2.1%	3.9%	0.4%	6.3%	2.8%
20	3,514	18.8%	-1.3%	84.4%	0.6%	3.0%	0.0%	21.7%	-3.8%	20.7%	0.9%	27.0%	0.1%	7.2%	0.9%	8.6%	2.7%
21	3,713	17.3%	-1.1%	87.4%	1.2%	2.8%	0.1%	31.6%	-5.0%	20.1%	0.3%	24.5%	-1.5%	3.8%	-0.2%	7.4%	5.3%
22	5,342	18.7%	-1.4%	85.0%	1.2%	2.3%	0.0%	17.4%	-3.3%	24.1%	1.1%	31.9%	-1.6%	5.5%	0.6%	8.5%	4.8%
23	3,190	18.7%	-2.5%	85.5%	2.0%	4.9%	0.3%	26.8%	-3.9%	18.4%	0.8%	27.9%	1.0%	5.1%	0.1%	6.6%	3.3%
Min		14.5%	-3.4%	77.3%	0.0%	1.3%	-0.6%	15.9%	-6.3%	16.0%	-0.8%	24.5%	-2.1%	3.0%	-0.3%	3.7%	1.8%
Max		28.2%	0.2%	88.9%	2.8%	5.4%	2.6%	31.6%	-1.5%	24.1%	2.2%	35.6%	2.2%	7.2%	0.9%	10.3%	6.1%
Mean	4,318	21.4%	-1.5%	83.3%	1.3%	2.8%	0.2%	21.9%	-4.2%	19.7%	0.8%	30.2%	0.1%	5.1%	0.3%	7.0%	4.0%
Std. Dev.	1,715	3.5%	0.9%	2.9%	0.8%	1.4%	0.6%	3.7%	1.1%	1.9%	0.8%	3.0%	1.2%	1.2%	0.4%	1.5%	1.3%
Coeff. of Var.	0.40	0.16	3.4%	0.03	-9.0%	0.49	20.6%	0.17	11.0%	0.10	-13.6%	0.10	-5.6%	0.23	8.8%	0.21	-49.3%

Table 3a. Station-level pharmacy measures -- Fiscal Year 2005

				prescri	rcent ibed any	polypi	ent with harmacy	within	nt dosed PORT	higher th	nt dosed nan PORT	hig	nt dosed h on	hig	nt dosed gh on	lower th	nt dosed an PORT	lov	nt dosed v on	lov	nt dosed w on
				-	sychotic		st week	recomme	nded range		nded range		ntionals	-	picals		nded range		ntionals		picals
VISN	Station	Station name	N	FY 2005	Change from FY 2004																
1	402 405	TOGUS WHITE RIVER JCT	494 176	88.5% 85.2%	-0.9% -2.0%	16.2% 11.3%	-0.6% 1.6%	61.3% 58.0%	0.4% -6.6%	15.6% 18.7%	3.0% 5.5%	4.9% 4.9%	0.1% -5.1%	17.1% 21.5%	3.5% 8.3%	24.7% 24.0%	-2.3% 1.1%	56.9% 63.4%	-1.9% -4.1%	14.9% 10.7%	0.5% 5.5%
1	518	BEDFORD	496	88.5%	-0.4%	20.5%	0.2%	54.9%	-1.3%	18.9%	-1.6%	12.2%	2.9%	19.4%	-3.3%	27.3%	3.1%	52.2%	-4.1%	18.0%	6.2%
1	523	BOSTON	1,196	81.2%	5.1%	12.4%	0.1%	58.5%	0.7%	14.7%	2.7%	5.9%	-0.5%	16.1%	3.0%	27.2%	-3.5%	56.9%	-2.2%	19.7%	-2.7%
1	608 631	MANCHESTER NORTHAMPTON	154 349	84.4% 88.5%	-1.5% 2.3%	12.3% 8.7%	1.1% -1.8%	56.2% 61.8%	1.7% -2.5%	11.5% 19.1%	2.6% 7.3%	3.0% 7.1%	-1.6% 2.7%	13.6% 20.6%	3.4% 7.9%	33.1% 19.1%	-3.5% -4.8%	72.7% 45.2%	7.6% -12.5%	19.4% 14.7%	-3.0% -3.0%
1	650	PROVIDENCE	490	83.1%	-2.7%	9.3%	1.7%	66.1%	-0.2%	16.7%	0.3%	11.8%	-3.6%	17.3%	0.9%	17.2%	-0.1%	43.1%	-3.0%	13.0%	0.9%
1	689	WEST HAVEN	987	84.0%	7.1%	10.0%	3.4%	63.2%	0.8%	13.3%	3.1%	6.8%	-1.2%	14.4%	3.7%	24.0%	-3.4%	55.0%	-0.2%	14.1%	-1.8%
2	528 526	UPSTATE N.Y. HCS BRONX	2,477 583	84.1% 82.2%	0.4% -1.3%	11.8% 5.8%	1.6% 0.3%	56.0% 62.4%	-3.6% -5.1%	16.0% 11.7%	0.8% 4.3%	7.6% 5.6%	1.5% -0.7%	17.7% 13.2%	0.1% 5.6%	28.9% 26.1%	3.2% 1.1%	56.0% 58.9%	-1.4% 3.0%	18.6% 14.2%	4.9% 0.5%
3	526 561	EAST ORANGE	1.325	85.8%	-0.3%	10.5%	0.3%	62.4%	-2.3%	18.3%	2.4%	15.2%	3.7%	18.4%	1.9%	19.5%	0.3%	44.2%	0.1%	11.0%	1.6%
3	620	MONTROSE	583	91.6%	1.0%	17.4%	1.3%	54.1%	-5.7%	19.5%	2.2%	14.5%	-2.5%	19.5%	3.0%	27.7%	4.3%	42.4%	3.2%	19.2%	3.6%
3	630	N.Y. HARBOR HCS	1,650	79.3%	1.1%	9.3%	-1.6%	63.2%	-0.2%	11.6%	0.1%	5.5%	-0.8%	13.0%	0.7%	25.6%	0.1%	52.4%	-2.1%	15.9%	1.7%
3	632 460	NORTHPORT WILMINGTON	658 350	83.9% 74.9%	4.6% 3.4%	12.0% 5.7%	1.1% -0.1%	59.1% 63.4%	-0.6% -2.6%	12.3% 15.3%	3.4% 6.3%	7.9% 6.0%	3.5% 0.5%	12.6% 17.6%	2.6% 8.0%	29.3% 21.8%	-2.4% -3.4%	45.7% 43.3%	-7.3% -5.8%	20.3% 14.2%	0.7% -2.3%
4	503	JAMES E VAN ZAND	213	79.8%	-3.8%	7.6%	2.4%	51.8%	-3.1%	11.2%	2.5%	3.3%	-3.4%	14.8%	5.6%	38.2%	1.8%	55.0%	-2.6%	27.8%	2.8%
4	529	BUTLER	137	86.1%	-0.5%	6.8%	-1.4%	53.4%	-7.6%	14.4%	5.5%	2.6%	-0.1%	18.6%	7.4%	33.1%	3.0%	57.9%	1.1%	19.8%	0.7%
4	540	CLARKSBURG	238	88.7%	2.7%	8.1%	-3.1%	62.6%	0.7%	10.4%	1.6%	1.9%	-1.9%	12.6%	2.3%	27.5%	-1.8%	75.0%	7.1%	12.0%	-5.2%
4	542 562	COATESVILLE ERIE	451 213	92.0% 77.9%	3.0% -1.6%	11.8% 6.6%	1.9% -2.3%	54.0% 55.4%	-11.6% 2.3%	16.4% 7.8%	4.7% 0.0%	12.8% 2.8%	-8.8% 0.7%	15.7% 9.0%	6.6% -0.1%	31.6% 37.3%	8.1% -2.9%	58.5% 72.2%	10.8% -4.4%	22.4% 26.9%	5.8% 1.2%
4	595	LEBANON	634	87.7%	0.3%	12.2%	-0.1%	65.8%	1.7%	8.1%	-2.3%	4.8%	-2.3%	8.4%	-2.1%	26.6%	0.7%	50.7%	-2.1%	18.1%	5.5%
4	642	PHILADELPHIA	1,479	83.9%	1.3%	7.4%	0.2%	60.4%	-3.6%	12.3%	2.6%	9.3%	0.6%	13.1%	3.4%	27.6%	1.3%	51.0%	-0.4%	16.8%	3.1%
4	646	PITTSBURGH-UNIV	1,282	87.8%	-1.6%	11.5%	-1.0%	60.6%	-0.7%	12.2%	0.6%	4.1%	-2.0%	14.0%	1.5%	28.1%	0.2%	50.6%	0.6%	17.7%	0.6%
4 5	693 512	WILKES BARRE BALTIMORE	584 1,099	84.1% 87.0%	1.0% 1.5%	6.7% 13.6%	-1.4% 0.6%	53.2% 61.7%	1.5% -3.2%	15.3% 16.8%	2.0% 3.6%	11.9% 15.0%	-1.8% 1.8%	15.6% 15.9%	3.5% 4.0%	31.6% 21.9%	-3.5% -0.2%	51.0% 43.2%	-6.1% 1.2%	22.9% 14.8%	-1.1% 0.6%
5	613	MARTINSBURG	341	87.4%	0.6%	10.7%	1.6%	64.1%	-5.7%	14.4%	3.1%	3.2%	1.6%	16.1%	3.2%	22.8%	3.0%	56.5%	1.5%	13.8%	2.8%
5	688	WASHINGTON	1,029	75.5%	-4.6%	9.5%	-0.2%	64.5%	-2.7%	14.8%	3.9%	10.4%	1.1%	15.1%	4.3%	21.0%	-1.0%	50.9%	-4.1%	16.2%	-1.2%
6	517	BECKLEY	156	94.2%	12.6%	10.2%	1.7%	59.9%	-6.0%	6.1%	-0.1%	0.0%	0.0%	8.3%	0.0%	34.0%	6.1%	60.0%	-0.5%	21.1%	6.7%
6 6	558 565	DURHAM FAYETTEVILLE NC	600 526	88.3% 87.3%	5.9% 2.7%	7.2% 6.3%	1.4% 0.8%	60.2% 63.6%	-0.2% -1.0%	14.9% 11.3%	-2.9% 2.0%	17.5% 5.2%	-1.1% 1.3%	12.8% 12.2%	-3.9% 2.1%	25.5% 25.1%	3.4% -1.0%	47.5% 66.2%	4.1% 0.0%	15.3% 16.7%	3.9% -1.5%
6	590	HAMPTON	651	87.3%	1.5%	7.0%	1.5%	62.5%	-5.2%	13.6%	1.4%	13.5%	-0.6%	13.3%	2.2%	24.3%	4.0%	47.3%	1.7%	16.0%	5.1%
6	637	ASHEVILLE-OTEEN	279	85.3%	2.3%	5.0%	-0.2%	62.2%	0.4%	8.8%	0.6%	4.2%	-0.4%	9.8%	0.4%	29.0%	-1.0%	39.6%	-9.6%	25.9%	4.0%
6	652	RICHMOND	548	84.1%	0.0%	14.3%	3.8%	59.4%	-4.2%	12.8%	3.2%	8.5%	-1.5%	13.4%	4.9%	29.1%	1.6%	51.9%	0.4%	18.5%	1.8%
6 6	658 659	SALEM SALISBURY	555 727	91.0% 88.4%	1.3% 0.3%	12.3% 10.9%	0.6% 1.1%	64.4% 61.3%	0.4% 0.7%	12.7% 14.5%	-1.3% 0.1%	10.5% 8.9%	-0.8% 0.1%	12.4% 15.2%	-1.3% -0.1%	24.4% 24.6%	1.7% -0.5%	40.3% 53.2%	-0.7% -3.1%	13.7% 16.8%	2.9% 0.1%
7	508	ATLANTA	1,300	82.7%	-3.5%	12.1%	2.1%	63.1%	-1.0%	14.9%	1.1%	9.1%	2.5%	15.5%	0.7%	22.4%	-0.2%	46.6%	0.0%	15.7%	0.0%
7	509	AUGUSTA	694	82.9%	-1.7%	3.5%	-1.2%	59.0%	-5.3%	17.9%	2.6%	8.6%	2.7%	19.6%	2.5%	23.1%	2.7%	50.5%	0.1%	16.7%	4.1%
7	521	BIRMINGHAM	822	88.3%	1.0%	10.1%	1.8%	66.4%	-0.6%	11.2%	-0.2%	5.4%	-2.9%	11.6%	0.1%	22.9%	0.6%	56.8%	2.6%	16.2%	0.6%
7 7	534 544	CHARLESTON COLUMBIA SC	617 809	86.7% 85.5%	2.2% 0.0%	10.5% 10.5%	1.4% 0.3%	62.2% 63.6%	-5.4% 1.6%	14.0% 13.7%	5.4% 1.2%	5.1% 11.5%	-0.7% -3.7%	15.4% 13.6%	6.7% 2.2%	25.0% 23.0%	0.9% -2.9%	60.2% 46.6%	7.7% -3.8%	14.7% 17.0%	-1.0% -1.6%
7	557	DUBLIN	414	80.2%	-0.7%	4.5%	1.9%	72.6%	-2.9%	5.7%	0.7%	2.4%	-0.3%	6.0%	0.7%	22.6%	3.1%	61.0%	2.6%	16.6%	1.6%
7	619	MONTGOMERY	977	84.9%	-0.1%	4.1%	1.0%	65.7%	-0.7%	9.9%	2.1%	5.0%	2.4%	10.4%	2.0%	24.4%	-1.8%	54.6%	-3.6%	19.2%	-1.7%
7	679	TUSCALOOSA	369	91.1%	0.3%	6.5%	-0.4%	65.2%	0.8%	14.0%	2.1%	12.4%	-1.1%	13.7%	3.7%	20.8%	-2.9%	41.0%	-1.1%	10.8%	-1.1%
8 8	516 546	BAY PINES MIAMI	930 1,315	82.6% 84.1%	-2.4% 0.8%	7.2% 9.0%	0.9% -1.3%	59.6% 53.8%	-5.0% 0.4%	18.5% 22.6%	2.9% -3.3%	9.3% 38.7%	0.2% -12.2%	20.5% 17.7%	3.7% 3.0%	22.0% 24.1%	2.2% 2.8%	51.6% 36.3%	0.9% 9.1%	14.2% 19.7%	2.8% 2.5%
8	548	W PALM BEACH	474	85.9%	1.2%	9.8%	-0.6%	56.3%	-4.4%	25.6%	4.6%	6.9%	-2.1%	27.5%	5.2%	18.9%	0.3%	50.0%	3.7%	13.5%	0.9%
8	573	N FL/S GA HCS	1,487	85.7%	0.7%	6.4%	-1.7%	68.4%	0.2%	10.8%	-1.3%	5.4%	-1.9%	11.5%	-0.9%	21.0%	0.6%	47.0%	-6.0%	15.9%	3.4%
8	672	SAN JUAN TAMPA	3,103	80.3%	0.3%	4.0%	0.6%	60.3%	-3.2%	3.3%	0.3%	1.8%	0.5%	3.5%	0.2% 0.7%	36.5%	2.9%	73.3%	0.4%	29.7% 16.5%	4.4%
8 9	673 581	HUNTINGTON	1,806 307	84.6% 88.6%	-1.5% 0.9%	6.6% 7.4%	-0.3% 2.2%	58.9% 53.7%	1.2% -1.5%	14.1% 9.9%	0.3% 0.7%	4.3% 1.8%	-2.0% -2.9%	17.3% 11.6%	1.5%	27.2% 37.5%	-1.5% 1.8%	53.9% 75.4%	2.3% 9.8%	26.8%	-0.7% 0.5%
9	596	LEXINGTON-LEESTO	330	87.0%	2.7%	7.0%	-1.1%	63.8%	-2.2%	13.9%	4.4%	2.3%	2.3%	15.4%	4.5%	22.6%	-2.3%	65.9%	8.5%	15.0%	-2.6%
9	603	LOUISVILLE	466	86.5%	-1.5%	6.9%	-1.0%	63.0%	-1.2%	6.2%	-0.8%	3.8%	-1.0%	6.6%	-0.7%	31.0%	1.9%	70.5%	0.6%	16.7%	1.8%
9	614	MEMPHIS	703	80.8%	1.9%	6.0%	3.0%	66.0%	-5.9%	17.4%	6.6%	6.6%	0.7%	21.1%	8.8%	16.5%	-0.9%	39.5%	-4.6%	7.1%	0.1%
9	621 626	MOUNTAIN HOME VA MID TENN HCS	336 1,218	83.3% 85.2%	6.0% 0.2%	6.1% 10.5%	2.4% 1.5%	57.9% 61.5%	-0.3% -1.5%	10.7% 13.9%	3.0% 2.6%	8.9% 9.9%	-1.9% 3.2%	11.3% 14.4%	4.1% 2.0%	31.4% 25.2%	-2.7% -0.9%	57.8% 43.3%	3.7% -1.1%	25.8% 18.4%	1.5% -0.7%
10	538	CHILLICOTHE	624	88.3%	2.4%	16.7%	0.5%	57.4%	-3.1%	11.8%	0.1%	8.6%	-0.6%	12.0%	0.9%	32.1%	3.2%	51.2%	1.6%	19.2%	4.8%
10	539	CINCINNATI	573	83.4%	-3.1%	9.8%	1.0%	65.9%	-0.8%	16.7%	6.0%	4.5%	-5.5%	17.9%	7.6%	17.8%	-4.9%	43.3%	-2.4%	13.5%	-4.7%
10	541 552	CLEVELAND-WADE P DAYTON	2,205	87.1%	4.8% 10.9%	8.0%	2.2% 3.4%	62.1% 62.6%	-2.8%	16.4%	3.4% -1.7%	7.0%	-2.7% -9.9%	18.5%	4.7%	21.9%	-0.5% -4.4%	54.1%	2.0% 1.0%	12.2%	0.1% -2.8%
10 10	552 757	COLUMBUS-IOC	522 431	83.0% 84.7%	10.9% 3.6%	5.8% 11.0%	3.4%	62.6% 61.1%	6.3% -2.1%	12.7% 7.4%	-1.7% 2.0%	19.5% 4.2%	-9.9% 1.5%	11.1% 7.7%	2.7% 2.0%	24.9% 31.5%	-4.4% 0.1%	48.3% 66.7%	1.0% 9.3%	18.5% 22.9%	-2.8% -1.2%
11	506	ANN ARBOR HCS	571	89.7%	1.3%	11.1%	2.9%	59.2%	0.6%	20.5%	0.1%	14.4%	5.9%	22.2%	-1.1%	20.5%	-1.1%	48.8%	-8.6%	11.7%	2.2%
11	515	BATTLE CREEK	948	90.1%	1.6%	9.8%	-2.0%	62.2%	-3.8%	16.6%	0.9%	14.3%	-1.2%	16.2%	2.0%	21.9%	2.6%	52.6%	6.2%	13.3%	3.9%

				prescr	rcent ibed any sychotic	polyp	ent with harmacy st week	within	nt dosed n PORT ended range	higher t	nt dosed han PORT inded range	hig	nt dosed gh on entionals	hig	nt dosed gh on picals	lower ti	ent dosed nan PORT ended range	lo	ent dosed ow on entionals	lo	ent dosed ow on picals
VISN	Station	Station name	N	FY 2005	Change from FY 2004	FY 2005	Change from FY 2004	FY 2005	Change from FY 2004	FY 2005	Change from FY 2004	FY 2005	Change from FY 2004	FY 2005	Change from FY 2004	FY 2005	Change from FY 2004	FY 2005	Change from FY 2004	FY 2005	Change from FY 2004
11	550		494	88.5%	0.2%	10.1%	4.4%	58.1%	-4.0%	21.7%	1.6%	11.1%	0.5%	23.6%	1.4%	20.4%	1.9%	52.8%	2.3%	9.3%	2.1%
11	553		1,103	87.9%	-0.1%	6.4%	-0.3%	66.5%	-2.3%	14.4%	2.0%	17.7%	-3.4%	12.9%	3.8%	19.2%	0.2%	37.1%	4.8%	13.3%	-0.7%
11 11	583 610		521 608	81.6% 87.8%	-3.1% 1.6%	10.6% 8.4%	-2.0% -2.0%	63.8% 62.2%	-0.6% 2.6%	15.1%	-2.3% -1.2%	13.3% 10.8%	-2.6% -2.3%	14.8% 16.3%	-2.4% -0.4%	22.4% 23.0%	3.0% -1.0%	48.2% 44.6%	8.9% -1.7%	15.1% 14.4%	2.3% 0.3%
11	655	SAGINAW	335	86.9%	3.3%	5.8%	-2.0%	60.8%	-3.2%	15.4% 14.1%	1.6%	4.6%	-2.3% -0.8%	16.0%	2.5%	25.1%	1.2%	43.1%	2.5%	19.0%	1.6%
12	537		1,217	81.2%	0.1%	6.2%	1.9%	64.4%	-1.3%	10.8%	0.6%	6.3%	-4.6%	11.4%	1.7%	25.0%	0.7%	57.5%	5.3%	18.5%	0.7%
12	556		319	81.2%	2.3%	10.4%	4.7%	61.0%	-6.6%	12.7%	2.1%	10.8%	-2.8%	12.6%	2.8%	27.0%	4.9%	50.8%	5.0%	18.2%	3.2%
12	578	HINES	626	85.1%	2.1%	10.4%	-0.4%	63.0%	-5.5%	10.5%	2.0%	4.9%	3.7%	11.1%	1.7%	26.6%	2.8%	55.6%	-9.4%	20.9%	4.7%
12	585		180	86.7%	-1.6%	21.2%	-1.4%	57.7%	-1.9%	16.7%	2.1%	10.0%	1.5%	19.2%	2.9%	26.3%	-0.9%	46.0%	-0.8%	15.2%	-1.9%
12	607		290	90.0%	3.8%	10.3%	2.7%	62.1%	-10.5%	18.8%	6.2%	6.8%	4.3%	20.5%	6.6%	19.2%	4.3%	68.2%	9.2%	9.8%	2.8%
12	676		286	90.2%	1.1%	11.2%	-0.3%	60.1%	-7.7%	19.8%	4.4%	1.9%	-3.1%	22.8%	5.8%	21.3%	2.9%	66.7%	8.3%	8.7%	2.2%
12	695	MILWAUKEE	686	84.0%	-0.1%	13.2%	0.3%	67.2%	-1.2%	10.1%	0.8%	6.3%	-1.2%	10.4%	1.1%	23.6%	0.4%	48.7%	1.1%	13.5%	0.9%
15	589		1.962	85.1%	0.4%	11.2%	1.5%	62.0%	-3.0%	17.1%	2.0%	11.4%	-0.7%	17.8%	2.6%	21.5%	0.9%	45.4%	3.5%	14.1%	0.7%
15	657		1,883	88.8%	-0.4%	14.3%	-1.3%	60.1%	-3.1%	12.6%	0.6%	8.0%	-0.1%	13.3%	1.1%	27.9%	2.5%	54.9%	0.7%	17.2%	3.6%
16	502	ALEXANDRIA	575	87.7%	-0.7%	11.3%	-1.5%	62.7%	-4.8%	17.9%	4.7%	10.6%	-0.4%	18.5%	5.5%	19.6%	0.2%	45.9%	-4.7%	13.7%	1.1%
16	520	GULF COAST HCS	1,281	86.5%	1.0%	5.8%	-2.0%	62.1%	-1.9%	18.1%	2.6%	14.6%	0.6%	18.8%	3.2%	20.6%	-0.3%	49.0%	4.3%	13.8%	0.0%
16	564		409	81.9%	0.8%	13.4%	2.4%	63.6%	-4.9%	13.4%	0.8%	10.3%	1.0%	13.4%	0.1%	23.6%	4.3%	42.3%	5.5%	16.5%	3.7%
16	580		1,462	88.9%	0.3%	10.9%	0.3%	65.1%	-2.4%	16.2%	1.7%	11.3%	0.0%	16.7%	1.9%	18.9%	0.7%	41.0%	2.2%	14.0%	0.8%
16	586	JACKSON	633	86.1%	1.6%	8.3%	2.4%	65.5%	-3.4%	13.0%	3.2%	6.2%	0.9%	13.8%	3.1%	21.8%	0.1%	48.1%	5.0%	16.7%	0.3%
16	598		728	88.5%	-0.1%	7.6%	0.9%	63.8%	-1.8%	13.4%	0.5%	7.1%	2.4%	14.7%	-0.3%	23.6%	1.2%	56.5%	0.9%	11.7%	1.3%
16	623		389	83.3%	-1.7%	13.0%	2.1%	58.3%	-6.9%	14.8%	6.4%	6.5%	3.0%	15.9%	6.9%	27.2%	0.5%	56.5%	10.1%	21.7%	0.1%
16	629		1,012	84.1%	-2.9%	10.5%	0.1%	61.3%	-1.4%	18.8%	3.0%	10.2%	2.1%	20.0%	2.8%	20.2%	-1.6%	40.1%	-9.6%	15.6%	2.0%
16	635		680	82.5%	-0.2%	6.2%	-0.7%	63.6%	-6.3%	7.5%	1.5%	2.0%	-1.0%	8.9%	2.1%	29.2%	5.0%	67.8%	12.9%	14.0%	0.4%
16	667		541	83.5%	1.5%	8.0%	1.7%	57.7%	-4.5%	8.9%	2.6%	0.0%	-2.7%	10.7%	3.6%	33.4%	1.4%	76.1%	5.3%	22.3%	2.6%
17	549		1,476	81.2%	-0.3%	8.3%	0.6%	66.4%	-1.7%	12.1%	1.9%	3.1%	0.6%	13.2%	2.3%	21.7%	-0.2%	59.0%	-1.2%	15.5%	0.2%
17 17	671 674	0/11/11/01/10	1,042	89.3% 81.5%	2.7% -1.1%	10.3% 6.5%	0.5% 0.3%	63.2% 65.1%	-2.4% -3.4%	17.0% 16.7%	-0.4% 1.9%	13.2% 10.9%	1.5% -0.9%	17.1% 17.3%	-0.8% 2.2%	20.3% 18.4%	2.4% 1.6%	42.5% 48.1%	-0.3% 3.2%	14.7% 13.7%	3.9% 1.7%
18	501		554	75.3%	-0.6%	3.6%	0.3%	67.4%	-3.4% -1.5%	6.2%	-1.5%	0.0%	-0.9%	7.1%	-1.4%	26.9%	2.8%	76.3%	1.3%	18.6%	2.9%
18	504	AMARILLO HCS	187	82.9%	-2.2%	5.2%	0.6%	51.6%	4.2%	4.5%	-1.3%	1.9%	0.5%	5.5%	-3.4%	43.9%	-2.9%	78.8%	0.3%	26.4%	6.4%
18	519		193	84.5%	1.1%	6.1%	0.5%	66.9%	4.4%	8.6%	-0.8%	3.7%	3.7%	9.3%	-1.5%	24.5%	-3.6%	66.7%	1.5%	15.7%	-5.9%
18	644	PHOENIX	889	75.6%	-4.1%	4.9%	-1.8%	67.1%	-2.2%	7.0%	0.1%	6.9%	-0.7%	6.8%	0.6%	26.0%	2.2%	56.6%	5.0%	16.1%	1.5%
18	649		234	74.8%	2.6%	10.3%	2.5%	54.9%	-6.0%	12.6%	1.7%	0.0%	-2.9%	14.9%	2.7%	33.1%	4.8%	62.5%	2.5%	23.0%	4.4%
18	678		464	80.0%	-3.4%	10.5%	1.6%	61.5%	-8.4%	15.1%	8.0%	2.9%	-7.4%	16.1%	9.5%	23.5%	0.4%	71.4%	4.8%	19.0%	1.1%
18	756	EL PASO HCS	300	80.7%	6.7%	4.1%	-2.2%	69.4%	-0.3%	9.5%	-0.3%	4.4%	1.0%	11.1%	-0.4%	21.1%	-0.9%	50.0%	-7.6%	9.4%	2.4%
19	436	FORT HARRISON	228	84.6%	-1.4%	10.9%	-1.9%	53.4%	-9.2%	22.8%	10.5%	6.5%	3.7%	24.6%	11.0%	24.9%	-0.3%	54.8%	4.8%	18.7%	0.1%
19	442	CHEYENNE	146	83.6%	-6.7%	12.3%	4.0%	68.0%	1.4%	11.5%	1.5%	0.0%	-11.1%	13.1%	4.0%	20.5%	-2.8%	54.5%	-8.4%	12.2%	1.0%
19	554	DENVER	904	83.4%	-1.6%	10.1%	0.3%	60.3%	-2.1%	14.7%	2.0%	7.7%	1.6%	16.1%	1.7%	25.7%	0.2%	50.7%	4.1%	15.6%	-1.6%
19	575	GRAND JUNCTION	162	89.5%	2.5%	15.2%	-2.7%	59.3%	4.3%	12.4%	-1.2%	2.7%	-3.8%	14.6%	-1.2%	29.0%	-3.9%	54.1%	1.9%	17.9%	-3.2%
19	660	SALT LAKE CITY H	464	90.1%	1.6%	9.6%	1.3%	58.1%	-7.3%	20.3%	7.8%	3.0%	3.0%	22.1%	8.3%	22.7%	-0.5%	60.6%	-3.8%	14.6%	-1.2%
19	666	SHERIDAN	140	92.9%	0.0%	16.2%	-6.4%	64.6%	-0.2%	13.1%	-1.7%	15.0%	5.5%	11.9%	-2.9%	22.3%	1.9%	45.0%	-2.6%	16.9%	2.2%
20	463	ALASKA HCS & RO	87	85.1%	-2.6%	13.5%	8.4%	67.6%	-6.8%	18.9%	1.0%	11.1%	-5.6%	19.1%	1.3%	13.5%	5.8%	44.4%	11.1%	8.8%	3.3%
20	531	BOISE	280	85.0%	-2.1%	7.1%	-1.3%	58.0%	-1.5%	14.3%	-1.8%	8.6%	-4.3%	15.8%	-0.6%	28.2%	3.3%	55.2%	-4.5%	18.9%	5.0%
20	648	PORTLAND	880	85.7%	1.9%	5.2%	0.2%	58.0%	-3.5%	13.0%	-0.9%	9.0%	-2.5%	13.9%	-0.6%	29.2%	4.3%	52.1%	-1.4%	22.2%	6.4%
20	653		347	88.8%	0.7%	8.8%	-1.2%	62.3%	-4.2%	12.0%	-0.8%	11.1%	1.6%	11.6%	-1.7%	26.3%	4.8%	54.0%	6.3%	18.1%	4.1%
20	663		1,285	85.3%	-1.4%	6.8%	-0.4%	69.3%	3.4%	13.4%	-2.6%	10.0%	-1.0%	13.7%	-2.9%	17.5%	-0.9%	47.9%	-1.2%	10.9%	0.3%
20 20	668 687		262 160	84.0% 83.8%	-1.3% 1.9%	10.0% 5.2%	1.6% -1.9%	70.0% 59.7%	-2.4% -2.2%	11.4% 11.2%	3.4% -1.5%	4.5% 0.0%	-0.2% -5.7%	11.7% 13.5%	3.7% -0.8%	19.1% 29.1%	-1.0% 2.9%	59.1% 44.4%	-2.8% -7.0%	14.1% 24.3%	-0.9% 9.0%
20	692		213	83.8%	5.1%	16.7%	-1.9% 1.4%	59.7% 68.3%	-2.2% 7.2%	16.7%	-1.5% 5.8%	6.9%	-5.7% 4.0%	13.5%	-0.8% 5.9%	29.1% 16.1%	-12.4%	55.2%	-7.0% -9.5%	24.3% 8.4%	9.0% -11.5%
20	358	MANILA	213	71.4%	5.1% 15.2%	6.7%	6.7%	66.7%	7.2% 11.1%	20.0%	5.8% 8.9%	33.3%	4.0% 8.3%	17.5%	5.9% 15.4%	20.0%	-12.4% -13.3%	33.3%	-9.5% 33.3%	15.4%	-11.5% -44.6%
21	459	HONOLULU	476	86.3%	-0.9%	11.7%	0.7 %	60.8%	-1.3%	11.7%	-2.3%	5.3%	-1.5%	12.7%	-2.6%	27.5%	3.4%	58.7%	1.8%	19.5%	3.7%
21	570		343	84.0%	-1.0%	6.3%	1.9%	66.0%	-11.3%	16.7%	7.6%	6.1%	6.1%	18.1%	7.6%	17.4%	3.6%	51.0%	7.5%	10.4%	1.9%
21	612		1.081	81.3%	-2.4%	9.2%	0.2%	63.9%	0.6%	15.6%	0.7%	8.9%	-1.3%	16.1%	0.9%	20.9%	-1.7%	48.6%	-1.1%	14.9%	-0.6%
21	640		1.001	87.6%	-0.5%	11.1%	-1.5%	56.8%	-10.5%	25.7%	8.2%	10.7%	0.2%	27.0%	8.9%	18.5%	2.8%	47.7%	0.1%	12.0%	3.7%
21	654		231	79.7%	-0.7%	7.6%	-3.9%	62.0%	-10.6%	18.5%	7.9%	9.1%	2.4%	19.5%	8.9%	20.1%	2.8%	45.5%	-7.9%	16.6%	4.9%
21	662	SAN FRANCISCO	560	78.0%	0.9%	12.1%	-0.5%	60.4%	-0.1%	14.9%	0.6%	5.5%	1.5%	16.1%	0.2%	25.2%	-0.2%	50.5%	-5.9%	18.0%	1.8%
22	593	LAS VEGAS	510	80.6%	-1.0%	8.8%	0.5%	66.4%	1.6%	13.1%	-0.9%	4.0%	-2.8%	14.0%	-1.1%	20.7%	-0.7%	54.0%	4.8%	15.6%	-0.9%
22	600		815	85.2%	-1.0%	15.4%	2.4%	56.5%	-4.7%	19.0%	0.7%	8.3%	1.3%	20.7%	-0.2%	24.8%	3.9%	49.0%	5.7%	16.7%	3.3%
22	605	LOMA LINDA	744	80.8%	-2.7%	8.3%	-1.3%	64.2%	-0.5%	12.1%	0.0%	9.6%	-1.5%	12.3%	0.4%	23.6%	0.2%	56.4%	-2.1%	16.8%	3.1%
22	664	VA SAN DIEGO HCS	1,010	86.9%	1.2%	8.7%	0.2%	61.8%	1.1%	15.3%	1.4%	9.6%	-1.9%	16.3%	2.1%	23.1%	-2.5%	51.4%	-3.6%	14.2%	-1.3%
22	691		2,263	81.1%	2.7%	7.7%	1.0%	64.9%	-4.0%	12.5%	1.7%	4.7%	0.0%	13.8%	1.9%	22.8%	2.4%	51.3%	4.1%	16.9%	2.5%
23	437		206	87.4%	0.9%	8.9%	2.7%	62.2%	-5.4%	19.4%	4.9%	4.5%	4.5%	20.6%	4.2%	19.4%	0.5%	86.4%	4.9%	10.3%	2.7%
23	438		245	87.8%	-0.7%	12.6%	-1.0%	60.0%	4.1%	14.4%	-0.9%	6.8%	-3.0%	15.3%	-0.3%	26.5%	-3.7%	56.8%	1.9%	18.0%	-4.0%
23	568		234	82.9%	-5.8%	14.4%	-1.3%	56.7%	3.9%	13.9%	-3.8%	4.3%	-5.8%	15.8%	-3.6%	30.9%	1.5%	63.0%	13.9%	21.5%	1.4%
23	618	MINNEAPOLIS	876	84.1%	-0.1%	7.1%	-0.1%	68.9%	-1.6%	12.1%	2.3%	7.3%	-0.8%	12.6%	2.8%	19.7%	-0.2%	52.7%	-4.0%	13.3%	0.4%

				prescr	rcent ribed any sychotic	polyp	cent with charmacy ast week	withir	nt dosed n PORT ended range	higher	ent dosed than PORT ended range	hi	ent dosed igh on entionals	hi	ent dosed gh on picals	lower t	ent dosed han PORT ended range	lo	ent dosed ow on entionals	lo	ent dosed ow on rpicals
					Change from		Change from		Change from		Change from		Change from		Change from		Change from		Change from		Change from
VISN	Station	Station name	N	FY 2005	FY 2004	FY 2005	FY 2004	FY 2005	FY 2004	FY 2005	FY 2004	FY 2005	FY 2004	FY 2005	FY 2004	FY 2005	FY 2004	FY 2005	FY 2004	FY 2005	FY 2004
23	636	VA NEB-WESTERN I	1,328	88.9%	0.7%	10.5%	-0.2%	61.1%	-1.1%	16.7%	2.0%	10.0%	-0.2%	18.0%	2.2%	22.4%	-1.0%	49.8%	0.3%	14.3%	0.2%
23	656	ST CLOUD	301	86.0%	-5.7%	4.6%	-2.6%	65.6%	0.9%	19.7%	1.7%	14.3%	3.2%	20.2%	1.3%	15.1%	-2.9%	45.7%	-9.8%	10.1%	1.3%
Min Max Mean			708	71.4% 94.2% 84.9%		3.5% 21.2% 9.5%	-6.4% 8.4% 0.4%	51.6% 72.6% 61.7%	-11.6% 11.1% -2.1%	3.3% 25.7% 14.1%	-3.8% 10.5% 1.9%	0.0% 38.7% 7.9%	-12.2% 8.3% -0.5%	3.5% 27.5% 15.0%	-3.9% 15.4% 2.4%	13.5% 43.9% 24.7%	-13.3% 8.1% 0.4%	33.3% 86.4% 53.5%	-12.5% 33.3% 0.9%	7.1% 29.7% 16.4%	-44.6% 9.0% 0.9%
Std. Dev Coeff. of			535 0.76	3.9% 0.05		3.4% 0.36	2.0% -14.6%	4.2% 0.07	3.7% -12.8%	4.1% 0.29	2.8% -5.2%	5.5% 0.70	3.2% -7.4%	4.3% 0.28	3.3% -10.0%	5.1% 0.21	3.1% -7.5%	9.7% 0.18	6.0% -7.7%	4.3% 0.26	4.9% -32.0%

Table 3b. Station-level pharmacy measures -- Fiscal Year 2005 (continued)

						_	i			_	i	_		_		_	i		
					ercent		ercent		ercent		ercent		ercent		ercent		rcent		ercent
					ribed any		ribed any		escribed		scribed		scribed		scribed		scribed		scribed
				CONV	entional/	aı	ypical	CIC	ozapine	Ulai	nzapine	que	tiapine	IISL	eridone	Zipi a	sidone	anp	iprazole
					Change from		Change from		Change from		Change from		Change from		Change from		Change from		Change from
VISN	Station	Station name	N	FY 2005	FY 2004	FY 2005	FY 2004	FY 2005	FY 2004	FY 2005	FY 2004	FY 2005	FY 2004	FY 2005	FY 2004	FY 2005	FY 2004	FY 2005	FY 2004
1	402	TOGUS	494	23.3%	-5.0%	84.2%	2.0%	6.2%	0.1%	28.4%	-1.7%	18.5%	0.1%	27.2%	2.3%	6.4%	1.2%	5.3%	3.0%
1	405	WHITE RIVER JCT	176	27.3%	-0.4%	80.7%	1.5%	5.3%	1.2%	32.0%	5.6%	12.7%	0.2%	20.0%	-6.4%	6.0%	-2.3%	7.3%	3.2%
1 1	518 523	BEDFORD BOSTON	496 1,196	26.2% 19.4%	-1.2% -1.2%	82.2% 84.6%	2.0% 1.0%	6.8% 5.0%	-1.0% 0.8%	19.4% 25.4%	-1.1% -1.8%	29.2% 23.0%	5.2% -2.5%	26.7% 30.0%	-1.2% 2.4%	3.6% 3.9%	-1.0% 0.5%	7.5% 5.1%	-1.9% 2.3%
1	608	MANCHESTER	1,196	25.4%	-6.7%	79.2%	6.1%	3.1%	0.1%	21.5%	-0.9%	23.1%	-2.5%	27.7%	3.8%	5.4%	3.9%	6.2%	-1.3%
1	631	NORTHAMPTON	349	13.6%	-0.7%	88.0%	0.1%	5.5%	-0.2%	27.5%	-2.1%	17.2%	-2.0%	35.6%	-3.3%	3.6%	0.7%	5.5%	5.2%
1	650	PROVIDENCE	490	12.5%	-2.9%	90.7%	4.2%	3.2%	-2.0%	27.5%	-2.9%	17.4%	4.4%	32.9%	-1.3%	6.9%	2.1%	8.6%	4.3%
1	689	WEST HAVEN	987	23.0%	-5.5%	81.9%	6.9%	6.2%	6.2%	24.7%	-1.3%	14.8%	1.3%	29.2%	-3.6%	6.2%	1.4%	5.5%	5.5%
2	528	UPSTATE N.Y. HCS	2,477	25.7%	-1.2%	79.6%	1.7%	3.2%	0.2%	20.1%	-4.9%	19.0%	1.0%	30.6%	2.2%	4.8%	0.7%	7.0%	2.6%
3	526	BRONX	583	25.9%	-0.4%	77.7%	0.8%	1.5%	0.2%	20.5%	-3.5%	13.4%	-0.3%	32.4%	0.3%	4.8%	0.9%	5.8%	1.9%
3	561	EAST ORANGE	1,325	24.9%	-2.2%	80.2%	1.0%	1.5%	-0.1%	19.3%	-1.1%	14.8%	0.2%	41.3%	-0.4%	2.5%	-0.7%	5.2%	3.3%
3	620	MONTROSE	583	30.9%	0.8%	79.8%	-0.1%	4.9%	0.9%	20.6%	-5.2%	14.0%	-2.5%	31.3%	0.8%	1.9%	0.0%	5.8%	3.4%
3 3	630 632	N.Y. HARBOR HCS NORTHPORT	1,650 658	25.1% 29.7%	-1.5% -1.5%	79.1% 79.3%	-0.2% 2.0%	0.8% 2.5%	-0.1% 0.4%	23.3% 25.9%	-4.6% -5.3%	18.0% 18.3%	2.1% 2.1%	29.5% 29.9%	-1.9% 2.1%	3.9% 1.3%	-0.2% 0.2%	8.5% 4.3%	4.4% 3.1%
3 1	460	WILMINGTON	350	25.6%	0.9%	79.3%	-1.1%	0.0%	0.4%	26.7%	-5.5% -6.0%	16.0%	0.8%	26.3%	2.1%	4.2%	-2.1%	3.1%	2.6%
4	503	JAMES E VAN ZAND	213	35.3%	1.2%	67.6%	-1.7%	1.2%	0.0%	16.5%	-6.7%	21.8%	6.2%	24.7%	3.3%	1.8%	-0.5%	4.7%	1.8%
4	529	BUTLER	137	32.2%	2.1%	72.9%	0.5%	0.8%	0.0%	23.7%	-4.7%	14.4%	-6.7%	22.0%	4.1%	4.2%	-1.5%	5.9%	5.1%
4	540	CLARKSBURG	238	24.6%	0.0%	79.1%	-2.2%	2.8%	0.1%	21.8%	-1.0%	25.6%	-6.0%	25.6%	4.2%	4.7%	-0.8%	2.4%	2.4%
4	542	COATESVILLE	451	22.7%	2.8%	86.0%	-0.7%	2.2%	0.1%	21.2%	-2.2%	19.5%	-1.0%	29.6%	-0.1%	2.9%	-2.5%	6.5%	3.6%
4	562	ERIE	213	21.7%	-4.6%	80.7%	0.3%	1.2%	0.6%	14.5%	-4.5%	15.1%	0.0%	45.2%	2.7%	2.4%	0.2%	1.2%	0.6%
4	595	LEBANON	634	26.3%	-6.2%	81.5%	4.7%	2.0%	1.1%	22.7%	-4.7%	16.9%	0.3%	30.4%	-0.7%	2.2%	-0.3%	8.1%	7.7%
4	642	PHILADELPHIA	1,479	31.3%	-1.3%	72.4%	1.2%	0.0%	0.0%	21.3%	-4.0%	19.1%	2.2%	26.0%	-0.2%	4.6%	0.1%	3.2%	2.6%
4	646 693	PITTSBURGH-UNIV WILKES BARRE	1,282 584	28.1% 29.1%	-2.2% -2.8%	78.9% 75.6%	0.7% 2.1%	4.4% 3.1%	0.4% -0.1%	20.2% 20.4%	-0.8% 3.1%	22.5% 14.7%	-0.5% 1.2%	25.8% 27.9%	1.0% -3.4%	4.5% 4.3%	0.7% 0.3%	2.7% 2.9%	0.3% 0.5%
5	512	BALTIMORE	1,099	24.5%	-2.7%	83.6%	1.7%	1.4%	-0.1%	28.7%	-1.6%	17.1%	2.2%	28.6%	-2.6%	4.3%	0.4%	5.8%	3.6%
5	613	MARTINSBURG	341	20.8%	1.3%	85.2%	-0.2%	0.7%	-0.3%	21.8%	-4.8%	17.8%	1.9%	22.5%	-0.9%	12.8%	-1.5%	13.1%	4.6%
5	688	WASHINGTON	1,029	13.6%	0.4%	88.4%	-1.0%	1.7%	0.3%	19.6%	-6.5%	18.1%	-1.9%	31.8%	-1.7%	6.8%	2.3%	14.9%	5.4%
6	517	BECKLEY	156	30.6%	1.2%	74.2%	-1.0%	0.0%	-0.8%	11.6%	-7.0%	16.3%	0.8%	40.8%	2.1%	2.7%	1.9%	6.8%	2.9%
6	558	DURHAM	600	30.2%	-1.7%	75.1%	3.7%	1.3%	-0.2%	14.0%	-6.1%	15.8%	4.0%	27.0%	-1.7%	5.3%	0.0%	12.8%	6.7%
6	565	FAYETTEVILLE NC	526	16.8%	0.5%	86.1%	0.0%	0.4%	0.0%	14.8%	-1.1%	14.2%	-2.4%	45.8%	-3.4%	3.5%	0.7%	10.0%	6.6%
6	590	HAMPTON	651	26.1%	-1.5%	78.0%	1.7%	0.9%	-0.6%	19.0%	-7.0%	19.5%	5.1%	27.1%	0.1%	6.9%	1.0%	4.8%	2.2%
6 6	637 652	ASHEVILLE-OTEEN RICHMOND	279 548	20.2% 28.0%	-8.1% -2.3%	81.1% 80.7%	7.6% 4.0%	0.0% 0.7%	0.0% -0.3%	13.0% 20.0%	-2.2% -0.3%	28.2% 22.6%	1.6% 2.3%	29.4% 31.5%	3.8% 0.5%	5.0% 3.3%	-1.9% -0.5%	6.3% 6.7%	4.6% 2.8%
6	658	SALEM	548 555	35.8%	-2.3% -0.4%	73.7%	4.0% 1.4%	4.6%	-0.3% -0.1%	18.6%	-0.3% -3.3%	13.7%	2.3% 0.8%	28.9%	-0.3%	5.0%	-0.5% 0.9%	3.4%	2.8% 1.3%
6	659	SALISBURY	727	19.3%	0.0%	85.1%	0.2%	1.9%	0.0%	16.8%	-4.3%	26.1%	3.5%	30.8%	-0.3%	8.2%	-1.2%	7.2%	3.5%
7	508	ATLANTA	1,300	19.3%	-0.4%	86.4%	0.4%	2.0%	0.1%	18.2%	-3.7%	24.0%	1.5%	31.2%	-1.1%	7.4%	1.0%	9.1%	4.7%
7	509	AUGUSTA	694	18.3%	-1.8%	83.5%	0.5%	7.7%	0.1%	27.8%	-3.9%	15.1%	-0.6%	25.9%	1.1%	4.9%	0.3%	1.7%	1.4%
7	521	BIRMINGHAM	822	15.3%	-1.2%	89.3%	1.9%	0.7%	0.3%	19.7%	-4.5%	25.1%	-2.0%	33.9%	2.7%	4.5%	-0.1%	10.3%	6.1%
7	534	CHARLESTON	617	22.1%	0.6%	83.7%	-0.2%	4.1%	0.2%	20.7%	-0.3%	16.3%	2.5%	34.0%	-0.8%	9.0%	-2.6%	3.9%	1.6%
7	544	COLUMBIA SC	809	18.9%	-1.7%	85.0%	1.5%	0.6%	0.2%	20.5%	-5.5%	24.4%	-4.2%	25.7%	2.6%	7.2%	0.1%	13.2%	9.6%
7 7	557	DUBLIN	414	12.3%	1.7%	91.0%	0.1%	0.3%	0.3%	14.8%	-6.2%	27.1%	2.6%	31.6%	5.0%	17.2%	0.6%	1.5%	-0.6%
7	619 679	MONTGOMERY TUSCALOOSA	977 369	14.4% 31.3%	1.3% -5.3%	87.8% 74.1%	-1.0% 4.0%	0.1% 4.8%	0.1% -0.2%	19.9% 13.4%	-4.3% -2.5%	25.0% 20.8%	-1.8% 2.0%	35.6% 30.1%	1.1% 1.1%	3.1% 1.8%	0.4% 0.3%	4.8% 4.2%	3.9% 3.9%
8	516	BAY PINES	930	21.0%	-0.1%	81.4%	0.3%	1.3%	0.8%	27.5%	-6.8%	18.1%	2.0%	27.9%	0.5%	3.8%	-0.3%	6.6%	4.5%
8	546	MIAMI	1,315	22.4%	-8.4%	82.3%	5.7%	2.3%	0.5%	16.6%	-4.0%	25.6%	7.8%	31.3%	0.5%	3.3%	-0.5%	7.5%	3.3%
8	548	W PALM BEACH	474	14.3%	-2.8%	89.4%	2.4%	2.0%	0.2%	28.7%	-7.0%	19.7%	2.6%	28.7%	-0.8%	5.7%	-2.3%	6.9%	6.4%
8	573	N FL/S GA HCS	1,487	15.9%	-3.1%	86.7%	1.1%	2.0%	-0.1%	23.9%	-5.5%	18.3%	2.4%	31.4%	-3.5%	3.8%	0.3%	10.4%	7.2%
8	672	SAN JUAN	3,103	15.3%	-2.1%	86.2%	1.9%	0.2%	0.0%	34.0%	-8.2%	22.5%	0.1%	21.5%	4.5%	2.4%	0.6%	7.0%	4.7%
8	673	TAMPA	1,806	27.7%	-4.4%	74.9%	3.1%	1.8%	0.1%	20.4%	-4.2%	14.7%	1.9%	31.7%	1.4%	5.3%	1.5%	4.8%	3.1%
9	581	HUNTINGTON	307	21.0%	-2.6%	82.4%	2.6%	0.0%	0.0%	14.0%	-4.4%	22.8%	1.5%	34.9%	3.3%	3.7%	-0.7%	7.7%	5.1%
9	596	LEXINGTON-LEESTO	330	15.3%	-1.9%	88.5%	1.0%	1.0%	-0.1%	24.0%	-4.2%	17.8%	-2.4%	36.9%	0.7%	3.1%	-0.2%	8.0%	6.2%
9	603 614	LOUISVILLE MEMPHIS	466 703	26.1% 29.4%	0.4% 1.1%	78.9% 74.1%	0.3% 0.3%	2.2% 1.6%	-0.3% -0.3%	18.1% 9.2%	-3.0% -9.1%	12.2% 13.6%	-1.8% -2.2%	32.8% 34.0%	-0.8% 4.8%	5.7% 9.3%	-2.0% 1.2%	7.4% 7.7%	5.5% 6.8%
9	621	MOUNTAIN HOME	336	29.4% 16.1%	-14.0%	74.1% 85.7%	12.1%	0.7%	-0.3% 0.3%	13.9%	-9.1% -3.1%	18.9%	-2.2% 2.3%	34.0%	4.8% 9.1%	9.3% 5.7%	-1.2%	9.3%	7.3%
9	021	MODITALITIONE	330	10.170	- 17.070	33.770	12.170	0.1 /0	0.570	10.070	-0.170	10.070	2.070	37.170	3.170	3.1 /0	- 1.2 /0	3.370	1.570

				Pe	ercent	Pe	ercent	Р	ercent	Pe	ercent	Pe	ercent	Р	ercent	Pe	rcent	Pe	ercent
				preso	ribed any	presc	ribed any	pre	scribed	pre	scribed	pre	scribed	pre	escribed	pres	scribed	pre	scribed
				conv	entional/	at	ypical	clo	zapine	olar	nzapine	que	etiapine	risp	peridone	zipra	asidone	arip	iprazole
					Channa fram		Change from		Change from		Change from		Channa from		Chanas from		Channa fran		Channa fram
VISN	Station	Station name	N	FY 2005	Change from FY 2004	FY 2005	Change from FY 2004	FY 2005	Change from FY 2004	FY 2005	Change from FY 2004	FY 2005	Change from FY 2004	FY 2005	Change from FY 2004	FY 2005	Change from FY 2004	FY 2005	Change from FY 2004
9	626	VA MID TENN HCS	1.218	27.4%	-0.1%	78.4%	0.8%	2.8%	0.0%	17.4%	-5.2%	24.0%	3.7%	27.3%	-1.5%	5.2%	-0.2%	5.1%	4.0%
10	538	CHILLICOTHE	624	37.9%	-1.8%	72.8%	0.1%	6.7%	-0.3%	8.5%	-8.0%	26.1%	3.3%	19.8%	1.8%	5.1%	0.6%	8.2%	2.9%
10	539	CINCINNATI	573	14.0%	-0.4%	89.7%	0.7%	4.4%	-0.3%	27.0%	-1.8%	24.9%	-0.4%	23.8%	1.6%	7.1%	1.8%	8.4%	2.2%
10	541		2,205	22.9%	-2.5%	80.9%	2.7%	6.6%	5.1%	24.8%	-5.1%	17.1%	-0.5%	22.5%	-3.1%	5.5%	0.0%	7.8%	7.7%
10	552	DAYTON	522	20.1%	-9.2%	83.6%	11.1%	1.8%	0.3%	22.2%	1.0%	16.6%	0.4%	35.1%	5.0%	3.2%	-0.2%	4.9%	4.6%
10 11	757 506	COLUMBUS-IOC ANN ARBOR HCS	431 571	19.7% 24.4%	-0.4% -0.9%	84.9% 83.4%	0.3% 2.6%	1.1% 5.7%	1.1% 0.2%	19.2% 26.8%	-2.1% -4.0%	28.5% 16.0%	-2.2% 5.6%	33.2% 30.9%	1.7% -0.5%	3.6% 3.1%	-0.7% 0.2%	4.7% 2.7%	4.4% 1.2%
11	515	BATTLE CREEK	948	20.5%	-0.9% -5.1%	86.1%	2.6%	4.1%	-0.2%	20.6%	-7.3%	19.4%	2.1%	32.3%	1.4%	2.8%	0.6%	5.3%	3.9%
11	550	ILLIANA HCS DANV	494	24.7%	-1.1%	83.3%	4.1%	2.1%	0.5%	27.5%	-2.0%	16.7%	2.1%	32.7%	3.3%	3.0%	-1.1%	2.7%	2.1%
11	553		1,103	23.9%	-0.9%	78.9%	0.2%	4.7%	0.5%	13.9%	-4.2%	14.2%	1.5%	43.3%	-0.8%	0.7%	0.0%	4.8%	3.0%
11	583	INDIANAPOLIS-10T	521	19.5%	-3.7%	85.6%	2.4%	2.1%	-0.5%	26.6%	-2.5%	19.3%	0.6%	32.0%	4.0%	8.5%	-1.5%	1.6%	1.4%
11	610	NORTHERN INDIANA	608	27.7%	-2.1%	75.7%	0.0%	1.3%	0.0%	22.5%	-3.2%	14.6%	0.6%	36.1%	-0.9%	3.7%	2.1%	1.7%	1.1%
11	655	SAGINAW	335	22.3%	-3.3%	81.4%	-0.2%	1.4%	-0.7%	19.6%	-0.5%	16.8%	-3.6%	36.1%	1.5%	3.1%	-1.1%	5.2%	2.7%
12	537 556	VA CHICAGO HCS NORTH CHICAGO	1,217 319	16.2% 25.1%	-1.7% 2.6%	85.8% 82.6%	1.3% 1.3%	1.0% 1.9%	0.3% 0.0%	19.2% 20.1%	-3.2% -4.0%	19.6% 16.6%	0.6% 3.2%	36.6% 27.0%	-2.0% -2.7%	2.7% 8.1%	-0.6%	8.7% 8.1%	6.7% 5.8%
12 12	578	HINES	626	15.2%	-0.3%	82.6% 87.8%	-0.5%	1.3%	0.0%	20.1%	-4.0% -6.2%	20.6%	3.2% 1.2%	38.5%	-2.7% -1.0%	5.3%	-0.3% -0.2%	6.8%	5.8% 4.6%
12	585	IRON MOUNTAIN	180	32.1%	0.9%	80.1%	-1.3%	1.3%	0.0%	23.7%	-0.8%	16.7%	1.4%	42.9%	-4.1%	1.9%	-0.2%	3.8%	3.8%
12	607	MADISON	290	16.9%	2.0%	85.8%	-1.6%	13.0%	-0.3%	20.7%	-5.6%	19.9%	1.6%	28.0%	4.7%	2.7%	0.4%	7.7%	-0.7%
12	676	TOMAH	286	20.9%	-2.1%	84.9%	1.7%	11.2%	2.0%	23.6%	-1.3%	10.5%	2.4%	34.5%	-2.3%	3.1%	0.0%	5.4%	0.8%
12	695	MILWAUKEE	686	27.4%	-1.7%	79.9%	1.9%	4.5%	0.1%	20.3%	-1.5%	16.8%	-0.6%	31.3%	0.1%	6.4%	1.2%	5.9%	2.7%
15	589		1,962	21.6%	-1.7%	83.9%	1.4%	2.8%	0.2%	17.0%	-3.4%	19.3%	-1.7%	31.0%	-2.0%	8.9%	1.5%	10.5%	8.8%
15	657		1,883	26.8%	-1.2%	81.9%	0.4%	0.0%	-1.3%	24.7%	-7.0%	22.2%	2.6%	30.5%	0.9%	3.3%	-0.4%	5.3%	3.4%
16 16	502 520	ALEXANDRIA GULF COAST HCS	575 1,281	16.9% 18.6%	0.0% -3.2%	86.9% 84.5%	-0.1% 1.5%	3.6% 0.9%	-0.1% 0.0%	26.2% 6.6%	-4.4% -1.5%	19.2% 25.8%	0.5% -2.4%	29.6% 37.3%	-5.3% -2.8%	3.8% 4.3%	0.8% 0.1%	11.3% 9.3%	8.7% 7.3%
16	564	FAYETTEVILLE AR	409	23.3%	-0.7%	84.8%	4.0%	1.5%	-0.4%	15.8%	-5.0%	28.4%	6.3%	29.3%	-2.6% -0.4%	3.0%	-3.0%	12.2%	4.4%
16	580		1,462	16.3%	-1.9%	88.2%	1.4%	2.0%	-0.1%	21.5%	-4.3%	20.4%	0.2%	33.6%	-0.4%	7.7%	1.4%	7.4%	3.7%
16	586	JACKSON	633	14.9%	-3.1%	88.1%	3.0%	0.7%	0.0%	18.5%	-6.4%	25.0%	1.6%	33.9%	2.8%	7.3%	0.2%	7.3%	7.3%
16	598	LITTLE ROCK	728	26.1%	0.1%	78.4%	0.2%	4.5%	-0.3%	14.1%	-5.1%	16.1%	0.8%	31.4%	0.6%	6.7%	0.4%	6.7%	3.0%
16	623	MUSKOGEE	389	14.2%	-3.2%	89.5%	3.2%	3.1%	0.9%	21.0%	-8.5%	24.4%	3.9%	34.0%	-0.2%	5.9%	3.7%	10.8%	6.5%
16	629		1,012	18.4%	-2.9%	85.2%	1.7%	0.8%	0.6%	22.4%	-3.2%	18.7%	0.4%	34.4%	-1.5%	7.6%	1.4%	5.9%	4.0%
16 16	635 667	OKLAHOMA CITY SHREVEPORT	680 541	27.1% 20.4%	2.9% -3.9%	77.7% 82.5%	-2.6% 4.0%	0.2% 0.7%	0.0% 0.2%	17.6% 12.8%	-7.9% -4.1%	21.4% 17.3%	-0.8% -0.3%	35.1% 36.1%	3.8% 2.8%	2.1% 6.2%	0.1% -0.9%	2.3% 13.7%	1.4% 6.9%
17	549		1.476	13.4%	-3.9% -0.4%	82.5% 89.6%	4.0% 0.2%	3.8%	0.2%	24.0%	-4.1% -5.7%	26.0%	-0.3% 1.4%	25.5%	2.8% -0.4%	6.1%	-0.9% 0.9%	8.5%	6.9% 4.1%
17	671	SAN ANTONIO	1.042	17.9%	-3.6%	86.5%	2.7%	1.8%	-0.1%	20.1%	-6.2%	15.7%	1.0%	36.7%	3.9%	6.9%	-0.7%	10.0%	6.3%
17	674		1,255	12.6%	-1.5%	90.2%	1.1%	3.4%	-0.6%	22.9%	-5.5%	25.0%	3.3%	32.7%	-1.8%	2.0%	0.1%	7.2%	5.8%
18	501	NEW MEXICO HCS	554	14.1%	0.6%	87.8%	-0.3%	3.4%	0.2%	14.9%	-4.3%	19.4%	0.5%	30.7%	-3.5%	5.8%	0.2%	13.4%	4.4%
18	504	AMARILLO HCS	187	33.5%	-11.9%	71.0%	12.5%	0.0%	-0.6%	12.3%	0.6%	23.2%	3.1%	25.2%	3.7%	4.5%	2.6%	5.2%	2.6%
18	519	WEST TEXAS HCS	193	16.6%	2.2%	85.9%	-1.0%	0.0%	0.0%	33.1%	-9.4%	20.2%	0.2%	26.4%	2.6%	1.8%	0.6%	8.0%	4.2%
18	644	PHOENIX	889	23.7%	0.7%	80.5%	-2.0%	2.1%	-0.3%	21.3%	-3.4%	17.9%	2.9%	30.5%	-1.2%	6.7%	-0.6%	1.8%	0.5%
18 18	649 678	NORTHERN ARIZONA SOUTHERN ARIZONA	234 464	22.9% 9.4%	1.8% -0.8%	84.6% 92.2%	0.2% 1.3%	0.0% 1.3%	0.0% -0.2%	17.1% 29.7%	-3.9% -3.9%	27.4% 21.8%	6.3% 3.8%	30.3% 35.0%	-7.7% 1.0%	9.7% 4.9%	6.7% -0.1%	2.9% 6.7%	0.4% 0.5%
18	756	EL PASO HCS	300	28.1%	-0.6%	74.4%	-2.2%	0.0%	0.0%	27.3%	-3.9% -2.0%	9.5%	-1.2%	23.6%	0.1%	12.0%	-0.1%	2.9%	1.9%
19	436	FORT HARRISON	228	16.1%	-1.7%	88.6%	1.4%	2.6%	0.1%	28.5%	-2.0%	20.7%	-5.4%	31.1%	3.0%	5.2%	1.2%	5.7%	1.8%
19	442	CHEYENNE	146	18.0%	-4.5%	87.7%	5.2%	2.5%	2.5%	27.0%	-1.3%	18.0%	-2.8%	20.5%	-1.2%	6.6%	2.4%	18.9%	8.0%
19	554	DENVER	904	27.5%	1.7%	78.2%	-1.0%	4.9%	0.0%	22.0%	-4.2%	15.5%	-1.5%	31.3%	3.1%	4.2%	-0.4%	4.0%	1.3%
19	575	GRAND JUNCTION	162	25.5%	-7.3%	84.8%	3.4%	1.4%	0.7%	21.4%	-2.9%	20.7%	4.3%	34.5%	-2.7%	0.7%	0.7%	10.3%	5.3%
19	660	SALT LAKE CITY H	464	15.8%	1.8%	90.0%	-1.3%	8.9%	0.1%	26.3%	-8.8%	20.6%	-1.2%	27.8%	3.1%	4.1%	0.7%	5.7%	5.7%
19	666	SHERIDAN	140	15.4%	0.6%	90.8%	-0.1%	3.8%	1.0%	27.7%	-11.7%	32.3%	9.1%	30.0%	0.4%	0.8%	0.1%	6.2%	-3.7%
20 20	463 531	ALASKA HCS & RO BOISE	87 280	12.2% 24.4%	4.5% -0.5%	91.9% 79.8%	-1.7% -0.9%	1.4% 3.4%	0.1% -0.3%	51.4% 13.4%	-3.8% -2.6%	16.2% 27.3%	8.5% 4.8%	24.3% 30.3%	0.0% -3.9%	5.4% 6.3%	0.3% 0.7%	2.7% 2.1%	-1.1% 1.7%
20	648	PORTLAND	280 880	24.4%	-0.5% -1.4%	79.8% 79.4%	-0.9% 0.8%	5.0%	-0.3% -0.2%	20.4%	-2.6% -3.4%	21.3%	4.8% -0.2%	14.2%	-3.9% -1.0%	8.0%	1.1%	12.3%	4.5%
20	653	VA ROSEBURG HCS	347	20.5%	0.2%	84.1%	-0.8%	1.6%	-0.3%	18.2%	-4.0%	23.7%	3.8%	31.8%	-1.0%	3.9%	-1.2%	8.1%	0.7%
20	663		1,285	17.3%	-1.8%	85.9%	1.2%	2.8%	0.2%	22.4%	-4.1%	16.5%	-0.2%	32.1%	2.0%	7.5%	0.7%	7.9%	2.7%
20	668	SPOKANE	262	10.0%	0.2%	93.2%	0.2%	1.4%	0.0%	23.2%	-4.4%	27.3%	0.2%	33.6%	0.5%	6.8%	0.7%	7.7%	4.0%
20	687	WALLA WALLA	160	20.1%	-7.6%	82.8%	5.1%	0.7%	0.0%	26.1%	-0.9%	17.9%	6.8%	33.6%	1.0%	3.0%	3.0%	3.0%	-4.2%
20	692	WHITE CITY	213	15.6%	-1.2%	89.2%	0.1%	1.6%	0.6%	22.0%	-5.5%	22.6%	-3.5%	25.3%	0.1%	13.4%	4.6%	14.0%	4.6%

				prescr	rcent ribed any entional	prescr	rcent ibed any pical	pre	ercent scribed zapine	pre	ercent scribed nzapine	pre	ercent scribed etiapine	pres	rcent scribed eridone	pres	rcent scribed asidone	pres	rcent scribed prazole
					Change from		Change from		Change from		Change from		Change from		Change from		Change from		Change from
VISN	Station	Station name	N	FY 2005	FY 2004	FY 2005	FY 2004	FY 2005	FY 2004	FY 2005	FY 2004	FY 2005	FY 2004	FY 2005	FY 2004	FY 2005	FY 2004	FY 2005	FY 2004
21	358	MANILA	21	20.0%	-24.4%	86.7%	31.1%	6.7%	6.7%	13.3%	2.2%	40.0%	17.8%	20.0%	8.9%	0.0%	0.0%	6.7%	6.7%
21	459	HONOLULU	476	18.2%	-1.2%	85.9%	2.0%	2.7%	0.9%	25.8%	-3.9%	23.4%	0.3%	30.9%	3.2%	5.1%	-2.4%	4.6%	2.4%
21	570	CENTRAL CALIFORN	343	17.0%	1.6%	86.5%	0.2%	0.0%	0.0%	31.6%	-5.9%	20.8%	-0.2%	26.7%	0.0%	3.8%	1.8%	4.2%	3.5%
21	612	NCHC MARTINEZ	1.081	16.6%	-2.1%	87.6%	1.3%	2.6%	0.2%	30.3%	-7.9%	20.7%	1.5%	21.4%	-5.4%	4.1%	1.1%	11.6%	11.2%
21	640	PALO ALTO-PALO A	1.001	17.0%	-0.8%	88.1%	0.9%	4.9%	-0.7%	40.8%	-3.4%	15.1%	-1.7%	23.5%	1.2%	2.3%	-0.2%	5.0%	2.5%
21	654	SIERRA NEVADA HC	231	12.0%	-2.5%	91.8%	1.0%	1.1%	0.1%	25.0%	-2.4%	32.6%	1.8%	23.4%	-4.0%	6.0%	-0.3%	7.6%	3.3%
21	662	SAN FRANCISCO	560	20.8%	-0.7%	85.4%	0.9%	1.8%	0.3%	24.5%	-5.2%	19.5%	1.5%	25.9%	-3.1%	4.6%	-1.2%	8.7%	4.2%
22	593	LAS VEGAS	510	12.2%	-2.2%	90.5%	2.2%	1.5%	0.0%	21.4%	-11.4%	34.6%	5.4%	23.4%	0.5%	8.5%	3.7%	6.8%	4.9%
22	600	VA LONG BEACH HC	815	22.6%	-1.1%	82.9%	0.4%	2.7%	-0.6%	14.3%	-4.0%	24.6%	2.4%	29.0%	-0.8%	10.1%	0.3%	11.1%	5.1%
22	605	LOMA LINDA	744	15.6%	-5.6%	88.0%	3.0%	2.7%	0.6%	23.0%	-1.9%	22.6%	1.2%	31.1%	0.6%	5.2%	0.6%	7.8%	2.9%
22	664	VA SAN DIEGO HCS	1,010	23.7%	-0.7%	81.2%	1.2%	1.5%	-0.2%	13.4%	-2.2%	18.0%	-0.5%	37.9%	-1.9%	4.9%	0.5%	8.9%	5.3%
22	691	GREATER LA HCS	2,263	17.2%	-0.6%	85.3%	0.7%	2.6%	0.0%	17.6%	-2.0%	24.8%	0.4%	32.2%	-3.0%	3.5%	0.0%	7.8%	5.0%
23	437	FARGO	206	12.2%	-2.9%	91.7%	3.4%	4.4%	-0.6%	37.8%	-8.6%	16.1%	-0.6%	21.1%	1.6%	5.6%	5.0%	10.6%	7.8%
23	438	SIOUX FALLS	245	20.5%	-2.5%	85.1%	1.3%	5.6%	0.2%	19.1%	-4.4%	24.7%	2.1%	33.5%	-0.7%	4.2%	0.6%	4.7%	3.3%
23	568	FORT MEADE	234	23.7%	-6.2%	81.4%	5.8%	5.2%	1.1%	11.9%	-1.3%	32.0%	0.0%	31.4%	0.0%	2.6%	-1.0%	6.2%	5.7%
23	618	MINNEAPOLIS	876	14.9%	0.1%	88.5%	0.1%	4.6%	0.3%	30.9%	-3.6%	17.4%	0.2%	24.7%	-0.5%	6.5%	-0.4%	6.6%	3.2%
23	636	VA NEB-WESTERN I	1,328	22.1%	-2.9%	82.9%	2.4%	4.1%	0.4%	22.6%	-3.9%	16.2%	0.6%	31.8%	2.4%	5.6%	-0.2%	7.2%	2.9%
23	656	ST CLOUD	301	13.5%	-5.9%	88.0%	2.4%	8.9%	0.2%	43.6%	-2.8%	18.1%	4.1%	16.2%	0.4%	1.5%	0.1%	2.7%	0.9%
Min				9.4%	-24.4%	67.6%	-2.6%	0.0%	-2.0%	6.6%	-11.7%	9.5%	-6.7%	14.2%	-7.7%	0.0%	-3.0%	1.2%	-4.2%
Max				37.9%	4.5%	93.2%	31.1%	13.0%	6.7%	51.4%	5.6%	40.0%	17.8%	45.8%	9.1%	17.2%	6.7%	18.9%	11.2%
Mean			708	21.3%	-1.9%	83.4%	1.7%	2.7%	0.2%	21.8%	-3.9%	20.2%	1.2%	30.2%	0.3%	5.0%	0.3%	6.8%	3.7%
Std. Dev.			535	6.0%	3.5%	5.1%	3.6%	2.3%	1.0%	6.6%	2.6%	5.1%	3.1%	5.5%	2.7%	2.6%	1.5%	3.2%	2.5%
Coeff. of	Var.		0.76	0.28	-5.8%	0.06	-19.2%	0.87	-5.7%	0.30	7.8%	0.25	-1.1%	0.18	-11.8%	0.53	-8.9%	0.47	-41.6%